Chao-Hung Wang1,2, Wei-Siang Chen1,3, Min-Hui Liu1,4, Chi-Ying Lee5, Mei-Ying Wang1,3, Chung-Yu Liang1,3, Chien-Ming Chu6, Huang-Ping Wu6, Wen-Hsin Chen1,3. 1. Heart Failure Research Center, Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, Keelung, Taiwan. 2. School of Medicine, Chang Gung University College of Medicine, Taoyuan, Taiwan. 3. Intensive Care Unit, Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, Keelung, Taiwan. 4. Department of Nursing, Chang Gung Memorial Hospital, Keelung, Taiwan. 5. Department of Medical Science, Institute of Bioinformatics and Structural Biology, National Tsing Hua University, Hsinchu, Taiwan. 6. Division of pulmonary, critical care and sleep medicine, Chang Gung Memorial Hospital, Keelung, Taiwan.
Abstract
OBJECTIVES: Hyperphenylalaninemia predicts poor outcomes in patients with cardiovascular disease. However, the prognostic value and factors associated with stress hyperphenylalaninemia (SHP) were unknown in critical patients in the cardiac ICU. DESIGN: Prospective observational study. SETTING: Single-center, cardiac ICU in Taiwan. PATIENTS: Patients over 20 years old with Acute Physiology And Chronic Health Evaluation II scores greater than or equal to 15 and/or ventilatory support in the cardiac ICU. INTERVENTIONS: We measured plasma phenylalanine levels serially during patients' stays in the ICU to investigate their prognostic value for 90-day mortality. Gene array was performed to identify genetic polymorphisms associated with SHP (phenylalanine level ≥ 11.2 μmol/dL) and to develop a Genetic Risk Score (GRS). We analyzed the associations between SHP and clinical factors and genetic variants and identified the correlation between pteridines and genetic variants. MEASUREMENTS AND MAIN RESULTS: The study enrolled 497 patients. Increased phenylalanine concentration was independently associated with increased mortality risk. Patients with SHP had a higher mortality risk compared with those without SHP (log rank = 41.13; p < 0.001). SHP was associated with hepatic and renal dysfunction and with genetic polymorphisms on the pathway of tetrahydrobiopterin (BH4) synthesis (CBR1 and AKR1C3) and recycling (PCBD2). Higher GRSs were associated with lower BH4 bioavailability in response to stress ( p < 0.05). In patients without SHP at baseline, those with GRSs gretaer than or equal to 2 had a higher frequency of developing SHP during the ICU stay (31.5% vs 16.1%; p = 0.001) and a higher mortality risk ( p = 0.004) compared with those with GRSs less than 2. In patients with SHP at baseline, genetic variants did not provide additional prognostic value. CONCLUSIONS: SHP in patients admitted to the ICU was associated with a worse prognosis. In patients without SHP, genetic polymorphisms associated with SHP measured using a GRS of greater than or equal to 2 was associated with the subsequent SHP and higher mortality risk.
OBJECTIVES: Hyperphenylalaninemia predicts poor outcomes in patients with cardiovascular disease. However, the prognostic value and factors associated with stress hyperphenylalaninemia (SHP) were unknown in critical patients in the cardiac ICU. DESIGN: Prospective observational study. SETTING: Single-center, cardiac ICU in Taiwan. PATIENTS: Patients over 20 years old with Acute Physiology And Chronic Health Evaluation II scores greater than or equal to 15 and/or ventilatory support in the cardiac ICU. INTERVENTIONS: We measured plasma phenylalanine levels serially during patients' stays in the ICU to investigate their prognostic value for 90-day mortality. Gene array was performed to identify genetic polymorphisms associated with SHP (phenylalanine level ≥ 11.2 μmol/dL) and to develop a Genetic Risk Score (GRS). We analyzed the associations between SHP and clinical factors and genetic variants and identified the correlation between pteridines and genetic variants. MEASUREMENTS AND MAIN RESULTS: The study enrolled 497 patients. Increased phenylalanine concentration was independently associated with increased mortality risk. Patients with SHP had a higher mortality risk compared with those without SHP (log rank = 41.13; p < 0.001). SHP was associated with hepatic and renal dysfunction and with genetic polymorphisms on the pathway of tetrahydrobiopterin (BH4) synthesis (CBR1 and AKR1C3) and recycling (PCBD2). Higher GRSs were associated with lower BH4 bioavailability in response to stress ( p < 0.05). In patients without SHP at baseline, those with GRSs gretaer than or equal to 2 had a higher frequency of developing SHP during the ICU stay (31.5% vs 16.1%; p = 0.001) and a higher mortality risk ( p = 0.004) compared with those with GRSs less than 2. In patients with SHP at baseline, genetic variants did not provide additional prognostic value. CONCLUSIONS: SHP in patients admitted to the ICU was associated with a worse prognosis. In patients without SHP, genetic polymorphisms associated with SHP measured using a GRS of greater than or equal to 2 was associated with the subsequent SHP and higher mortality risk.
Authors: Shane J F Cronin; Corey Seehus; Adelheid Weidinger; Sebastien Talbot; Sonja Reissig; Markus Seifert; Yann Pierson; Eileen McNeill; Maria Serena Longhi; Bruna Lenfers Turnes; Taras Kreslavsky; Melanie Kogler; David Hoffmann; Melita Ticevic; Débora da Luz Scheffer; Luigi Tortola; Domagoj Cikes; Alexander Jais; Manu Rangachari; Shuan Rao; Magdalena Paolino; Maria Novatchkova; Martin Aichinger; Lee Barrett; Alban Latremoliere; Gerald Wirnsberger; Guenther Lametschwandtner; Meinrad Busslinger; Stephen Zicha; Alexandra Latini; Simon C Robson; Ari Waisman; Nick Andrews; Michael Costigan; Keith M Channon; Guenter Weiss; Andrey V Kozlov; Mark Tebbe; Kai Johnsson; Clifford J Woolf; Josef M Penninger Journal: Nature Date: 2018-11-07 Impact factor: 49.962
Authors: Peter Würtz; Aki S Havulinna; Pasi Soininen; Tuulia Tynkkynen; David Prieto-Merino; Therese Tillin; Anahita Ghorbani; Anna Artati; Qin Wang; Mika Tiainen; Antti J Kangas; Johannes Kettunen; Jari Kaikkonen; Vera Mikkilä; Antti Jula; Mika Kähönen; Terho Lehtimäki; Debbie A Lawlor; Tom R Gaunt; Alun D Hughes; Naveed Sattar; Thomas Illig; Jerzy Adamski; Thomas J Wang; Markus Perola; Samuli Ripatti; Ramachandran S Vasan; Olli T Raitakari; Robert E Gerszten; Juan-Pablo Casas; Nish Chaturvedi; Mika Ala-Korpela; Veikko Salomaa Journal: Circulation Date: 2015-01-08 Impact factor: 29.690
Authors: Jennifer K Bendall; Gillian Douglas; Eileen McNeill; Keith M Channon; Mark J Crabtree Journal: Antioxid Redox Signal Date: 2014-03-14 Impact factor: 8.401